Eltrombopag--a Novel Approach for the Treatment of Chronic Immune Thrombocytopenic Purpura: Review and Safety Considerations

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2010 Aug 7

PMID 20689640

Authors

Lucy Cook

Nichola Cooper

Affiliations

Soon will be listed here.

Abstract

Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction of platelets, these agents increase the production of platelets, presumably overwhelming the immune system resulting in normal platelet counts in individuals refractory to or dependent on other therapies. These treatments are well tolerated and in randomized controlled trials show an improvement in platelet counts and a reduction in bleeding in refractory patients. This article summarizes the development of this new class of drug and evaluates the safety and efficacy of eltrombopag in patients with ITP.

References

Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View

Duffy K, Price A, Delorme E, Dillon S, Duquenne C, Erickson-Miller C . Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002; 45(17):3576-8. DOI: 10.1021/jm0255365. View

. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120(4):574-96. DOI: 10.1046/j.1365-2141.2003.04131.x. View

Duffy K, Darcy M, Delorme E, Dillon S, Eppley D, Giampa L . Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001; 44(22):3730-45. DOI: 10.1021/jm010283l. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Kuter D, Begley C . Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002; 100(10):3457-69. DOI: 10.1182/blood.V100.10.3457. View

Gainsford T, Roberts A, Kimura S, Metcalf D, Dranoff G, Mulligan R . Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood. 1998; 91(8):2745-52. View

Metcalf D, Burgess A, Johnson G, Nicola N, Nice E, DeLamarter J . In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol. 1986; 128(3):421-31. DOI: 10.1002/jcp.1041280311. View

Erickson-Miller C, Delorme E, Tian S, Hopson C, Stark K, Giampa L . Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005; 33(1):85-93. DOI: 10.1016/j.exphem.2004.09.006. View

10.

Bussel J, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L . Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9664):641-8. DOI: 10.1016/S0140-6736(09)60402-5. View

11.

Yang C, Li Y, Kuter D . The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999; 105(2):478-85. View

12.

Bussel J, Marks K . How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(8):424-5. DOI: 10.1038/ncpgasthep1185. View

13.

Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R . Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-8. DOI: 10.7326/0003-4819-132-5-200003070-00005. View

14.

Erhardt J, Erickson-Miller C, Aivado M, Abboud M, Pillarisetti K, Toomey J . Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009; 37(9):1030-7. DOI: 10.1016/j.exphem.2009.06.011. View

15.

Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M . Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001; 98(12):3241-8. DOI: 10.1182/blood.v98.12.3241. View

16.

Jenkins J, Williams D, Deng Y, Uhl J, Kitchen V, Collins D . Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-41. DOI: 10.1182/blood-2006-11-057968. View

17.

Kimura H, Ishibashi T, Shikama Y, Okano A, Akiyama Y, Uchida T . Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood. 1990; 76(12):2493-500. View

18.

Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S . Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery.... Blood. 1999; 93(9):2798-806. View

19.

Basser R, Rasko J, Clarke K, Cebon J, Green M, Grigg A . Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997; 89(9):3118-28. View

20.

Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel J . International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2009; 115(2):168-86. DOI: 10.1182/blood-2009-06-225565. View